DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust ...

We recently compiled a list of the Jim Cramer’s List of Stocks that Finished Dead Last. In this article, we are going to take ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $100.0 for DexCom, spanning the last three months.

Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San ...

A top healthcare stock to own over the years has been DexCom (NASDAQ: DXCM). The company makes continuous glucose monitors (CGMs) that help diabetics track their glucose levels. CGMs are necessary ...

DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...

The availability of new sensors like G6 and G7 in new international ... while revenues increased 15% to $1 billion. Dexcom expects total revenues to be in the band of $4-$4.05 billion for 2024 ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against the other Jim Cramer stocks that finished dead last. In a recent episode of Mad Money, Jim Cramer ...

DexCom's stock crashed after the company lowered its guidance last quarter. The rationale for the adjustment was a bit concerning, prompting analysts to wonder if there are greater problems facing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...